Clinical Trials Directory

Trials / Terminated

TerminatedNCT00946283

Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome

Probiotic Enteric Regimen For Easing Complications of Transplant : A Pilot Study (PERFECT Trial)

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Rutgers, The State University of New Jersey · Academic / Other
Sex
All
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Probiotics, such as Lactobacillus, may be effective in preventing infections in patients with suppressed immune systems. PURPOSE: This phase I trial is studying the side effects and how well giving enteral nutrition, including Lactobacillus, works in preventing infections in patients undergoing donor stem cell transplant for hematologic cancer or myelodysplastic syndrome.

Detailed description

OBJECTIVES: * To determine if patients who are treated with a probiotic-containing diet develop infection with one of the probiotic microorganisms while undergoing allogenic hematopoietic stem cell transplantation for a hematologic malignancy or myelodysplastic syndrome. OUTLINE: Patients receive oral Lactobacillus rhamosus GG (Culturelle DS) once daily beginning when blood counts have recovered without filgrastim (G-CSF) or sargramostim (GM-CSF) support for 3 consecutive days and continuing for 1 year after transplantation.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTLactobacillus rhamnosus GGCulturelle DS (Lactobacillus GG) will be administered one capsule (10 billion live lactobacillus GG) daily with water

Timeline

Start date
2010-03-01
Primary completion
2013-05-01
Completion
2015-10-14
First posted
2009-07-24
Last updated
2017-02-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00946283. Inclusion in this directory is not an endorsement.